Bloomberg Anywhere Remote Login Bloomberg Terminal Demo Request


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

Bloomberg Customers

Markets & Finance

USB Piper Upgrades Mylan Labs to 'Outperform'

USB Piper upgraded Mylan Labs (MYL) to outperform.

Analyst Timothy Coan says he upgraded from market perform on improved visibility for fiscal 2005 (March), an attractive return from his $31 price target.

Coan says Mylan announced its intention to launch a generic version of Johnson & Johnson's Duragesic, a patch for pain, no later than July 23, 2004. He notes this compares to his current projection of a Jan. 23, 2005 launch. With the launch of a major drug with limited competition coming this summer, he believes Mylan's fiscal 2005 has just gained a significant new driver. He sees $1.23 fiscal 2004 earnings per share, and raised the $1.50 fiscal 2005 estimate to $1.56.

blog comments powered by Disqus